Fitness
Fitness

MRM Health and Biocodex Partner to Build Production Capacity for CORAL® Therapies

By Dr. Elena Voss ·

Strategic Partnership Strengthens Commercial Supply

The partnership between MRM Health and Biocodex marks a key step. It consolidates future commercial production capabilities. This collaboration integrates MRM Health's advanced microbiome science. It also leverages Biocodex's industrial experience. The primary aim is to support lead asset MH002. It also covers other CORAL®-based programs. Support spans the full product lifecycle. This includes process development and clinical manufacturing. It extends to future commercial supply. Access to specialized infrastructure addresses a critical need. MRM Health strengthens its readiness for pharmaceutical partnerships.

Biocodex Invests in New Production Infrastructure

Biocodex will invest 15 million euros over the coming years. The funds target new production infrastructure. This is dedicated to live biotherapeutics. It includes anaerobic production capabilities. The facility is located at Biocodex's new pharmaceutical site in Beauvais, France. The French company will finance, build, own, and operate the facility. MRM Health contributes its anaerobic production expertise. This input guides the design and implementation. The infrastructure is designed for CORAL®-derived products. It also supports other live biotherapy programs.

Executive Perspectives on the Collaboration

„Developing next-generation live biotherapeutics requires production capabilities as sophisticated as the science behind them,”said Dr. Sam Possemiers, CEO of MRM Health. „Together with Biocodex, we are establishing a specialized, scalable production pathway. This covers clinical development through future commercial manufacturing. This partnership strengthens the readiness of our own portfolio. It also covers CORAL® programs developed with pharmaceutical partners for future commercialization. This brings microbiome-based therapies closer to patients.”Nicolas Coudurier, CEO of Biocodex, highlighted that this strategic collaboration strengthens the partnership begun last year. By combining expertise, the two companies help consolidate European industrial capabilities. This step is essential for supporting the development of these new therapeutic approaches. It ultimately allows patients to benefit from them.

Flexible Support Structure for Multiple Programs

This partnership functions as a support structure for multiple MRM programs. Biocodex can offer process development services. It also provides analytical testing and GMP manufacturing. These are available for individual CORAL® programs under specific agreements. MRM Health gains access to the production infrastructure. This covers its own, partnered, or licensed CORAL® programs. The non-exclusive nature preserves MRM Health's flexibility. It allows engaging additional or alternative manufacturing partners where needed. This flexible collaboration provides a supplementary production pathway. It supports lead candidate MH002 and the broader portfolio. It reduces the need for pharmaceutical partners to establish specialized pathways independently.

Scalable Industrial Support from Development

Scalable industrial support spans development to commercial supply. MRM Health has developed proprietary expertise. This involves scalable production of complex bacterial consortia. It uses its unique CORAL® manufacturing technology. The new infrastructure builds on this competency. This offers a coordinated pathway for technology transfer. It covers process development, clinical manufacturing, and future commercial supply. The facility provides flexible production infrastructure at multiple scales. For MRM Health, this enables progress for MH002 and other portfolio programs. It moves from development to late-stage clinical manufacturing. It ultimately targets commercial-scale production. The capacity to support CORAL® programs will expand as the portfolio advances. Initial process development and pilot manufacturing activities are expected to start by 2027. Commercial-scale production is targeted from 2030.